Loading clinical trials...

Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy | Clinical Trials | Clareo Health

RECRUITINGPHASE3

Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

An Open-label Extension of APG-20 Study to Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With Partial Lipodystrophy

NCT06679270•Amryt Pharma

View on ClinicalTrials.gov

Summary

This Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy

Eligibility

Age

13 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age ≥13 years of age, inclusive, at the time of signing the informed consent form (ICF).
•2. Subjects must have completed the Parent study APG-20 and, in the opinion of the Investigator and Sponsor, have been compliant with study procedures through Parent study Month 12 visit.
•3. Negative pregnancy test (urine or serum) for female subjects of childbearing potential
•4. Female subjects must be postmenopausal (defined as cessation of menses for at least 1 year), surgically sterile (hysterectomy, bilateral oophorectomy, or tubal ligation), or willing to use a highly effective method of contraception (such methods include combined \[estrogen and progestogen containing\] hormonal contraception associated with inhibition of ovulation: oral/intravaginal; transdermal/progestogen-only hormonal contraception associated with inhibition of ovulation: oral/injectable; implantable/intrauterine device \[IUD\]/intrauterine hormone-releasing system \[IUS\]/bilateral tubal occlusion/vasectomized partner/sexual abstinence) for the duration of the study (from the time they sign an ICF, until 4 weeks after the last dose of study treatment). Hormonal contraception alone (including oral, injectable, transdermal, and implantable) is not acceptable; an additional barrier method must be used. Intravaginal hormonal contraception or IUS alone are allowed per Investigator's discretion. Subjects on oral contraceptives will not be required to discontinue medication. Subjects will not be permitted to commence oral contraceptives while taking study treatment during the study.
•6. Subjects who are blood/egg/sperm donors should be willing to halt donations during the study and for 4 weeks following their last dose of study treatment.
•7. Subjects who are willing to provide informed consent/assent prior to any study-specific procedures. If a minor, the subject has a parent or legal guardian able to read, understand, and sign the ICF and/or a Child Assent Form (if applicable), communicate with the Investigator, and understand and comply with the protocol requirements. Adolescent subjects must also read and understand the Child Assent Form.
•8. Subjects who are willing to follow the dietary restrictions recommended by the Investigator.

Exclusion Criteria

•1. Severe hypersensitivity reactions to the study treatment of the Parent study APG-20.
•2. Known to have tested positive for human immunodeficiency virus (HIV) or known to be diagnosed with HIV-related LD. Positive HIV test in countries requiring HIV testing.
•3. Are immunocompromised or receiving immunomodulatory drugs.
•4. Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m2 calculated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) for subjects ≥18 years of age and by Bedside Schwartz for subjects \<18 years of age.
•5. Diagnosis of clinically significant hematological abnormalities (including but not limited to clinically significant leukopenia, neutropenia, bone marrow abnormalities, leukemia or lymphoma, or clinically significant pathological lymphadenopathy).
•6. Malignancy that is ongoing/not in remission or that currently requires or has required active treatment within the past year (with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ \[e.g., breast carcinoma, cervical cancer in situ\] that have undergone potentially curative therapy).
•7. For females only: currently pregnant (confirmed with a positive pregnancy test) or breastfeeding.
•8. Any condition where, in the opinion of the Investigator, participation in this study may pose a significant risk to the subject.

Locations (7)

University of Alabama

Birmingham, Alabama, United States

Flourish Research

Boca Raton, Florida, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

University of Michigan

Ann Arbour, Michigan, United States

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

UT Southwestern Medical Center

Dallas, Texas, United States

The Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Key Dates

Start Date

October 14, 2024

Primary Completion Date

March 1, 2028

Completion Date

December 1, 2028

Last Updated

February 2, 2026

Enrollment

ESTIMATED participants

Conditions

Familial Partial Lipodystrophy

Interventions

Metreleptin

DRUG

Contacts

Lori Hartnett, PhD

CONTACT

+3905212791 clinicaltrials_info@chiesi.com

The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy

NCT02527343

Familial Partial Lipodystrophy

View study

COMPLETEDPHASE2

CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy

NCT02654977

Familial Partial LipodystrophyNonalcoholic Steatohepatitis+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 2, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions